Ibuzatrelvir: Difference between revisions
CSV import |
CSV import |
||
| Line 2: | Line 2: | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| verifiedrevid = | | verifiedrevid = 477002123 | ||
| image = Ibuzatrelvir.svg | | image = [[File:Ibuzatrelvir.svg|thumb|Chemical structure of Ibuzatrelvir]] | ||
| image2 = <!-- Another image if available --> | | image2 = <!-- Another image if available --> | ||
| | | tradename = PAXLOVID | ||
| | | class = Antiviral | ||
}} | }} | ||
'''Ibuzatrelvir''' is an [[antiviral drug]] that is | '''Ibuzatrelvir''' is an [[antiviral drug]] that is used in the treatment of [[COVID-19]]. It is part of a class of medications known as [[protease inhibitors]], which work by inhibiting the action of the [[SARS-CoV-2]] main protease, an enzyme critical for the viral replication process. | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Ibuzatrelvir functions | Ibuzatrelvir functions by targeting the [[3C-like protease]] (3CL<sup>pro</sup>) of the [[SARS-CoV-2]] virus. This protease is essential for the cleavage of the viral polyprotein into functional units necessary for viral replication. By inhibiting this enzyme, Ibuzatrelvir effectively halts the replication of the virus within the host cells. | ||
== | ==Pharmacokinetics== | ||
Ibuzatrelvir is administered orally and is rapidly absorbed into the bloodstream. It undergoes hepatic metabolism and is primarily excreted via the renal route. The drug has a half-life that allows for convenient dosing schedules, typically once or twice daily, depending on the severity of the infection and the patient's renal function. | |||
== | ==Clinical Use== | ||
Ibuzatrelvir is | Ibuzatrelvir is indicated for the treatment of mild to moderate [[COVID-19]] in adults and pediatric patients who are at high risk for progression to severe disease, including hospitalization or death. It is most effective when administered early in the course of the infection. | ||
==Side Effects== | ==Side Effects== | ||
Common side effects of Ibuzatrelvir include [[nausea]], [[diarrhea]], and [[headache]]. Some patients may experience [[liver enzyme]] elevations, and it is recommended to monitor liver function during treatment. Serious adverse effects are rare but can include [[allergic reactions]] and [[hepatic impairment]]. | |||
==Drug Interactions== | |||
Ibuzatrelvir can interact with other medications that are metabolized by the [[cytochrome P450]] enzyme system, particularly CYP3A4. Caution is advised when co-administering with drugs such as [[anticoagulants]], [[anticonvulsants]], and certain [[antidepressants]]. | |||
== | ==Development and Approval== | ||
Ibuzatrelvir was developed in response to the global [[COVID-19 pandemic]] as part of efforts to provide effective oral antiviral therapies. It received emergency use authorization from regulatory agencies based on clinical trial data demonstrating its efficacy in reducing viral load and preventing severe outcomes in high-risk patients. | |||
==Related | ==Related Pages== | ||
* [[COVID-19 pandemic]] | * [[COVID-19 pandemic]] | ||
* [[Antiviral drug]] | * [[Antiviral drug]] | ||
Latest revision as of 01:26, 6 March 2025
Antiviral drug
| Ibuzatrelvir | |
|---|---|
[[File: | |
| INN | |
| Drug class | Antiviral |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ibuzatrelvir is an antiviral drug that is used in the treatment of COVID-19. It is part of a class of medications known as protease inhibitors, which work by inhibiting the action of the SARS-CoV-2 main protease, an enzyme critical for the viral replication process.
Mechanism of Action[edit]
Ibuzatrelvir functions by targeting the 3C-like protease (3CLpro) of the SARS-CoV-2 virus. This protease is essential for the cleavage of the viral polyprotein into functional units necessary for viral replication. By inhibiting this enzyme, Ibuzatrelvir effectively halts the replication of the virus within the host cells.
Pharmacokinetics[edit]
Ibuzatrelvir is administered orally and is rapidly absorbed into the bloodstream. It undergoes hepatic metabolism and is primarily excreted via the renal route. The drug has a half-life that allows for convenient dosing schedules, typically once or twice daily, depending on the severity of the infection and the patient's renal function.
Clinical Use[edit]
Ibuzatrelvir is indicated for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe disease, including hospitalization or death. It is most effective when administered early in the course of the infection.
Side Effects[edit]
Common side effects of Ibuzatrelvir include nausea, diarrhea, and headache. Some patients may experience liver enzyme elevations, and it is recommended to monitor liver function during treatment. Serious adverse effects are rare but can include allergic reactions and hepatic impairment.
Drug Interactions[edit]
Ibuzatrelvir can interact with other medications that are metabolized by the cytochrome P450 enzyme system, particularly CYP3A4. Caution is advised when co-administering with drugs such as anticoagulants, anticonvulsants, and certain antidepressants.
Development and Approval[edit]
Ibuzatrelvir was developed in response to the global COVID-19 pandemic as part of efforts to provide effective oral antiviral therapies. It received emergency use authorization from regulatory agencies based on clinical trial data demonstrating its efficacy in reducing viral load and preventing severe outcomes in high-risk patients.
